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Abstract
The histone methyltransferase enhancer of zeste 2 (EZH2) is known to be a polycomb protein homologous to
Drosophila enhancer of zeste and catalyzes the addition of methyl groups to histone H3 at lysine 27 (H3K27).
We previously reported that EZH2 was overexpressed in various types of cancer and plays a crucial role in the cell
cycle regulation of cancer cells. In the present study, we demonstrated that EZH2 has the function to mono-
methylate lysine 120 on histone H2B (H2BK120). EZH2-dependent H2BK120 methylation in cancer cells was
confirmed with an H2BK120 methylation-specific antibody. Overexpression of EZH2 significantly attenuated the
ubiquitination of H2BK120, a key posttranslational modification of histones for transcriptional regulation. Concor-
dantly, knockdown of EZH2 increased the ubiquitination level of H2BK120, suggesting that the methylation of
H2BK120 by EZH2 may competitively inhibit the ubiquitination of H2BK120. Subsequent chromatin immuno-
precipitation–Seq and microarray analyses identified downstream candidate genes regulated by EZH2 through
the methylation of H2BK120. This is the first report to describe a novel substrate of EZH2, H2BK120, unveiling
a new aspect of EZH2 functions in human carcinogenesis.
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Introduction
Enhancer of zeste 2 (EZH2) belongs to polycomb group (PcG) protein
and is a member of the polycomb repressor complex 2 (PRC2) that
methylates histone H3 at lysine 27 (H3K27), a repressive mark that
maintains epigenetic silencing of genes. EZH2 is active only when it
is associated with other PRC2 core components embryonic ectoderm
development (EED), suppressor of zesta 12 homolog (SUZ12), and
RBBP4 (retinoblastoma binding protein 4; RbAp48). The PRC2 com-
plex is responsible for repressing of a large number of genes that are
essential for development and differentiation. PcG proteins specify
positional information such as antero-posterior patterning, through
activating or repressing the stable state of Hox gene expression. In ad-
dition to these well-established functions in embryonic development,
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a series of studies have suggested that PcG proteins may influence both
Hox-dependent and Hox-independent downstream pathways that
control cell proliferation. We previously demonstrated that EZH2
was overexpressed in various types of human cancer, and its over-
expression was correlated with a negative outcome in patients with
non-small-cell lung carcinoma (NSCLC) after surgical resection [1].
Importantly, selective inhibitors targeting EZH2 have recently devel-
oped, and they showed the growth-inhibitory effects of tumor cells
[2,3]. These results indicate that EZH2 is a promising target for devel-
opment of cancer treatment. Although the transcriptional regulation
mechanism by EZH2 through methylation of H3K27 has already been
well studied, additional functions of EZH2 through methylation of
other substrates still remained unclear.
Posttranslational modification of the four core histones is a com-
monly important process during the regulation of gene activation
and repression. Histone modifications are also involved in various
cellular processes, including DNA damage response and alternative
splicing. Histone H2B is one of the four core histones involved in
chromatin formation in eukaryotic cells. Featuring a main globular
domain and a long N-terminal tail, H2B is involved with the struc-
ture of the nucleosomes of the “beads on a string” structure. As post-
translational modifications of histoneH2B, acetylation, phosphorylation,
ubiquitination, and sumoylation have already been reported [4–8].
Among these modifications, histone H2B lysine 120 monoubiqui-
tination (H2BK120ub) is known to be a key histone modification
that plays critical roles in the transcriptional regulation as well as
higher order chromatin organization in many species [9]. H2BK120ub
is associated with a high level of gene expression in human cells [10].
This histone modification is also induced after DNA damage and
has been indicated to have a critical role in the maintenance of
replication-dependent histone mRNA 3′-end processing [11]. The
human ring finger protein 20 (RNF20)/RNF40 complex is the major
H2B E3 ligase [12]. At the structure level, monoubiquitination of
H2BK120 interferes with compaction of chromatin, resulting in open
chromatin fibers that display greater accessibility to transcription fac-
tors and their coregulators [13]. Several studies implicate H2BK120ub
in developmental processes including that optical embryonic stem
cell differentiation requires dynamic changes in H2B ubiquitination
patterns in a timely and well-coordinated manner [7,14].
In this study, we identified that the histone methyltransferase
EZH2 methylates H2BK120 and competitively inhibits ubiquiti-
nation of this lysine residue in cancer cells. This is the first report
describing identification of histone H2B as a novel substrate of
EZH2 and demonstrating the biologic significance of the histone
H2B methylation in human carcinogenesis.
Materials and Methods
Cell Culture
CCD-18Co, HFL1, HCT116, SW480, RT4, MCF7, HeLa, and
293T cells were from American Type Culture Collection (ATCC,
Manassas, VA) in 2001 and 2003 and tested and authenticated by
DNA profiling for polymorphic short tandem repeat (STR) markers.
SBC5, RERF-LC-AI, and Alexander cells were from Japanese
Collection of Research Bioresources (JCRB) in 2001 and tested and
authenticated by DNA profiling for polymorphic STR markers.
All cell lines were grown in monolayers in the following appro-
priate media: Dulbecco’s modified Eagle’s medium for RERF-LC-AI
and 293T cells; Eagle’s minimum essential medium for CCD-18Co,
SBC5, MCF7, and HeLa cells; Leibovitz’s L-15 for SW480 cells;
McCoy’s 5A medium for RT4 and HCT116 cells; RPMI 1640
medium for Alexander cells; and Ham’s F-12KMedium for HFL1 cells
supplemented with 10% FBS and 1% antibiotic/antimycotic solution
(Life Technologies, Carlsbad, CA). All cells were maintained at 37°C in
humid air with 5% CO2 condition (CCD-18Co, HFL1, SBC5,
RERF-LC-AI, HCT116, SW480, Alexander, RT4, MCF7, HeLa,
and 293T) or without CO2 (SW480). Cells were transfected with
FuGENE 6 (Roche Applied Science, Penzberg, Germany) according
to the manufacturer’s protocols [15,16].
Antibodies
The following primary antibodies were deployed: anti-FLAG [M2;
Sigma-Aldrich (St Louis, MO); dilution used in Western blot (WB):
1:5000, immunocytochemistry (ICC): 1:100], anti-EZH2 (NCL-L-
EZH2; Leica, Solms, Germany; dilution used in WB: 1:500), anti–
histone H2B (ab1790; Abcam, Cambridge, United Kingdom; dilution
used in WB: 1:1000), anti–Ubiquityl-Histone H2BK120 (No. 5546;
Cell Signaling Technology, Danvers, MA; dilution used in WB:
1:1000, ICC: 1:50), and anti–actin, beta (ACTB; No. 4967; Cell
Signaling Technology; dilution used in WB: 1:1000). The anti–K120-
methylated H2B antibody [Sigma-Aldrich; dilution used inWB: 1:500,
ICC: 1:100, immunohistochemistry (IHC): 1:5000] was produced in
rabbit immunized with a synthetic peptide.
In Vitro Methyltransferase Assay
For the in vitro methyltransferase assay, recombinant Histone
H2B (No. 14-410; Millipore, Billerica, MA) was incubated with
EZH2 enzyme complex (No. 51004; BPS Bioscience, San Diego,
CA) using 2 μCi of S-adenosyl-L-[methyl-3H] methionine (Perkin-
Elmer, Waltham, MA) as the methyl donor in a mixture of 10 μl
of methylase activity buffer (50 mM Tris-HCl at pH8.8, 10 mM
DTT, and 10 mM MgCl2), for 1 hour at 30°C. Proteins were resolved
on a 5% to 20% sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis (SDS-PAGE) gel (Ready Gel; Bio-Rad Laboratories, Hercules,
CA) and visualized by MemCode Reversible Stain (Thermo Fisher
Scientific, Waltham, MA) and fluorography.
Mass Spectrometry
Histone H2B samples reacted with EZH2 were separated on SDS-
PAGE and stained with Coomassie brilliant blue. The excised
Histone H2B bands were reduced in 10 mM tris(2-carboxyethyl)
phosphine (Sigma-Aldrich) with 50 mM ammonium bicarbonate
(Sigma-Aldrich) for 30 minutes at 37°C and alkylated in 50 mM
iodoacetamide (Sigma-Aldrich) with 50 mM ammonium bicarbonate
for 45 minutes in the dark at 25°C. Trypsin GOLD (Promega,
Fitchburg, WI) solution was added with the enzyme-to-protein ratio
at 1/50 (wt/wt) and incubated at 37°C for 16 hours. The resulting
peptides were extracted from gel fragments and separated on a 0.1 ×
200 mm homemade C18 column using 45-minute linear gradient
from 2% to 35% acetonitrile in 0.1% formic acid with flow rate at
200 nl/min. The eluting peptides were analyzed with QSTAR Elite
QqTOF system (AB Sciex, Framingham, MA) in the smart information-
dependent acquisition mode of the Analyst QS software 2.0 (AB Sciex).
The acquired mass spectrometry (MS) and tandem mass spectrometry
(MS/MS) peak lists were analyzed with in-house Mascot server version
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2.4.01 (Matrix Science, Boston, MA) to identify peptide sequences.
We finally accepted the assigned peptides with expectation value less
than 0.05 as the positive identification in Mascot Database search.
Western Blot Analysis
Samples were prepared from the cells lysed with CelLytic M
Cell Lysis Reagent (Sigma-Aldrich) [17], and whole-cell lysates or
immunoprecipitation (IP) products were transferred to nitrocellulose
membrane. Protein bands were detected by incubating with HRP-
conjugated antibodies (GE Healthcare, Little Chalfont, United
Kingdom) and visualizing with Enhanced Chemiluminescence (GE
Healthcare). We declare that our blots were evenly exposed in each
membrane and that the blots are not clopped to the bands.
Immunocytochemistry
Cultured cells were fixed in 4% paraformaldehyde in 0.1 M phos-
phate buffer (pH 7.4) at room temperature for 30 minutes, permea-
bilized in 0.1% Triton X-100 (Sigma-Aldrich) for 3 minutes on ice,
and blocked with BLOCK ACE (Yukijirushi, Sapporo, Japan) for
1 hour at room temperature. Fixed cells were incubated with primary
antibodies overnight at 4°C. Then incubated with Alexa Fluor–
conjugated second antibody (Life Technologies) and observed using
a Leica confocal microscopy [18,19].
Immunohistochemical Analysis
The K120 monomethylation status of histone H2B in clinical
tissues were examined by immunohistochemical analysis [1,17].
EnVision+ kit/HRP kit (Dako, Carpinteria, CA) was applied, and
slides of paraffin-embedded lung tumor specimens were processed
under high pressure (125°C, 30 seconds) in antigen-retrieval solution,
high pH 9 (S2367; Dako), treated with peroxidase-blocking regent,
and then treated with protein-blocking regent (K130, X0909; Dako).
Tissue sections were incubated with a rabbit anti-H2BK120me1
polyclonal antibody, followed by HRP-conjugated secondary anti-
body (Dako). Antigen was visualized with substrate chromogen (Dako
Liquid DAB Chromogen; Dako). Finally, tissue specimens were
stained with Mayer haematoxylin (Hematoxylin QS; Vector Labora-
tories, Burlingame, CA) for 20 seconds to discriminate the nucleus
from the cytoplasm. The intensity of H2BK120 methylation was
evaluated using the following criteria: strong positive (scored as 2+),
brown staining in >50% of tumor cells completely obscuring cyto-
plasm; weak positive (1+), any lesser degree of brown staining appre-
ciable in tumor cell cytoplasm; and absent (scored as 0), no appreciable
staining in tumor cells. Cases were accepted as strongly positive if
two or more investigators independently defined them as such.
Detailed clinical information of lung and colony tissues is described
in Tables W1 and W2.
siRNA Transfection
Small interfering RNA (siRNA) oligonucleotide duplexes were
purchased from Sigma-Aldrich for targeting the human EZH2 tran-
script. siNegative control (siNC) was used as a control siRNA. The
siRNA sequences are described in Table W3. siRNA duplexes (100 nM
final concentration) were transfected into bladder and lung cancer cell
lines with Lipofectamine 2000 (Life Technologies) [20].
Immunoprecipitation
Transfected 293T or SBC5 cells were lysed with CelLytic M Cell
Lysis Reagent (Sigma-Aldrich) containing a complete protease inhib-
itor cocktail (Roche Applied Science). In a typical immunoprecipita-
tion reaction, 300 μg of whole-cell extract was incubated with an
optimum concentration of primary antibody. After the beads had
been washed three times in 1 ml of TBS buffer (pH 7.6), proteins
that bound to the beads were eluted by boiling in Lane Marker
Reducing Sample Buffer (Thermo Fisher Scientific).
Chromatin Immunoprecipitation–Seq
Chromatin immunoprecipitation (ChIP) assays were performed
using ChIP Assay kit (Millipore) according to the manufacturer’s pro-
tocol. Briefly, the fragment of EZH2 and chromatin complexes was
immunoprecipitated with anti-H2BK120me1 (Sigma-Aldrich) and
anti-FLAG (M2; Sigma-Aldrich) antibodies 36 or 48 hours after trans-
fection with siRNAs and pCAGGS-n3FC (Mock) or pCAGGS-n3FC-
EZH2 (3× FLAG-EZH2) vectors, respectively. ChIP-DNA samples
were end repaired, A tailed, and finally ligated with DNA adaptors.
Subsequently, samples were size fractionated (175-225 bp) on a 2%
tris-borate-EDTA (TBE) agarose gel. Fractionated ChIP-DNA samples
were amplified using KAPA Library Preparation Kit (Kapa Biosystems,
Woburn, MA). After a final polymerase chain reaction amplification
step (18 cycles), the resulting DNA libraries were analyzed by an
Agilent Technologies 2100 Bioanalyzer (Santa Clara, CA), and DNA
libraries were sequenced on Illumina GAIIx (San Diego, CA).
ChIP-Seq Data Analysis
Sequencing data were acquired from the Illumina GAIIx sequencer
[21]. ChIP-Seq reads were aligned using Burrows-Wheeler Aligner
software (version 0.62-r126) to the human genome (University of
California, Santa Cruz, CA; hg19) with default settings [22]. Burrows-
Wheeler Aligner’s default mismatch criteria for creating the mismatches
was set up that mismatch allowance was 3%, which means that allow-
ance of InDels (insert and deletion) was at leastmore than 3 bp in 100-bp
reads. When same reads mapped to the same genomic position, a
maximum of two reads mapping to the same position were used.
For enriched-region (peak) identification (peak calling), we used the
Model-based Analysis of ChIP-Seq (MACS; Harvard University,
Boston, MA; version 1.4.1) algorithm [23,24]. We set up a band with
300 bp, P value of 1.00e-06, model fold between 10 and 30 (default) to
call peaks representing enriched H2BK120me1 marks and EZH2-
located regions. To prospect the peak detection of enhancer region,
tags detected were aligned in each gene set within 10 kbp upstream
from transcription start sites or 10 kbp downstream from transcrip-
tion terminal sites. We used the statistical software DESeq (European
Molecular Biology Laboratory, Hamburg, Germany), an R package,
to normalize the number of tags detected in each gene region and
calculated the ratio of samples and controls [25]. Normalized intensity
value of genes was ordered as a heatmap using hierarchical clustering
in Cluster 3.0 software (Stanford University, Stanford, CA).
Microarray Hybridization and Statistical Analysis
Microarray analysis to identify downstream genes was described
previously [20,26,27]. Purified total RNA was labeled and hybridized
onto Affymetrix GeneChip U133 Plus 2.0 oligonucleotide arrays
(Affymetrix, Santa Clara, CA) according to the manufacturer’s instruc-
tions. Probe signal intensities were normalized by robust multichip
average (RMA) and Quantile (using R and Bioconductor).
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ChIP Assay
ChIP assays were performed using ChIP Assay kit (17-295;
Millipore) according to the manufacturer’s protocol. Briefly, the
fragment of K120-ubiquitinated H2B and chromatin complexes
in HEK293 cells was immunoprecipitated with an anti–Ubiquityl-
Histone H2BK120 antibody. After DNA fragments bound to
K120-ubiquitinated H2B were eluted out, an aliquot was subjected
to quantitative real-time polymerase chain reaction reactions. Pro-
tein A Agarose/Salmon Sperm DNA (16-157; Millipore) was used
as a negative control. Primers were designed near the transcriptional
start site of each gene, and their sequence information is shown in
Table W4.
Results
EZH2 Methylates Lysine 120 on Histone H2B
To identify a novel substrate of EZH2, we conducted in vitro
methyltransferase assays using recombinant histone proteins as well
as nonhistone proteins that play important roles in human carcino-
genesis. Consequently, we identified that EZH2 appeared to meth-
ylate histone H2B in addition to histone H3 (Figure W1). To
validate this result, we performed in vitro methyltransferase assays
using different amount of EZH2 enzymes and confirmed histone
H2B methylation by EZH2 in a dose-dependent manner (Figure 1A).
Subsequently, we conducted liquid chromatography (LC)-MS/MS
Figure 1. EZH2 methylates lysine 120 of histone H2B both in vitro and in vivo. (A) In vitro methyltransferase assay of H2B. Recombinant
H2B and 3H-SAM were incubated in the presence or absence of EZH2 enzyme complex (No. 51004; BPS Bioscience), and the reaction
products were analyzed by SDS-PAGE, followed by fluorography (upper panel). The membrane was stained with Ponceau S (Sigma-Aldrich;
lower panel). BSA was used as a control. (B) The MS/MS spectrum corresponding to the monomethylated H2B 109-125 peptide. The
14-Da increase of the lysine 120 residue was observed, demonstrating the monomethylated lysine 120. Score and Expect show Mascot
Ion Score and Expectation value in Mascot Database search results, respectively. (C) Determination of the titer and specificity of the anti-
monomethylated K120 H2B antibody analyzed by ELISA. (D) Validation of an anti-monomethylated K120 H2B antibody. Recombinant
H2B-WT or H2B-K120A proteins and 3H-SAM were incubated in the presence or absence of EZH2 enzyme complex, and the re-
action products were analyzed by SDS-PAGE, followed by Western blot analysis with an anti-monomethylated K120 histone H2B antibody
(upper panel) and stained with MemCode Reversible Stain (lower panel). SAHH, S-adenosyl-L-homocysteine hydrolase. (E) Immuno-
cytochemical analysis of HeLa and 293T cells. Cells were stained with an anti-FLAG antibody [M2; Sigma-Aldrich; Alexa Fluor 594 (red)],
an anti-H2BK120me1 antibody [Sigma-Aldrich; Alexa Fluor 488 (green)] and 4′,6′-diamidine-2′-phenylindole dihydrochloride [DAPI (blue)].
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analysis to define the methylation site on H2B and found that
H2BK120 was monomethylated by EZH2 (Figure 1B). We then gener-
ated anti–H2BK120-methylated antibodies using an H2BK120-meth-
ylated peptide (Figure W2). Among four different lots of the antibodies
we obtained, we confirmed by slot blot analysis that H2BK120me1B
showed the best quality of the result (Figure W3). In addition, ELISA
analysis using this H2BK120-methylation–specific antibody clearly in-
dicated that this antibody recognized the K120-methylated peptide but
did not react to the unmethylated peptide, supporting the high speci-
ficity of this antibody against H2BK120 methylation (Figure 1C). To
further verify the quality of the H2BK120-methylation antibody, we
prepared both wild-type H2B (H2B-WT) and K120-substituted
H2B (H2B-K120A) recombinant proteins and performed in vitro
methyltransferase assays using EZH2. The H2BK120-methylation sig-
nal was increased in a dose-dependent manner, and the signal was com-
pletely diminished when H2B-K120A protein was used as a substrate
(Figure 1D). Using the methylation-specific antibody, we performed
immunocytochemical analysis after transfection of EZH2 vectors into
HeLa cells to confirm EZH2-dependent H2BK120 methylation
in vivo and detected the strong staining of methylated H2BK120 in
EZH2-overexpressing cells (Figure 1E ). Taken together, EZH2 can
methylate H2BK120, and this methylation is also observed in vivo.
H2BK120 Monomethylation Is Increased in Cancer Cells
Because we previously found that the histone methyltransferase
EZH2 was overexpressed in various types of cancer [1], we examined
whether the methylation level of H2BK120 was enhanced in human
cancer cells. Firstly, we prepared cell extracts of two noncancerous
cell lines (CCD-18Co and HFL1) and nine cancer cell lines (SBC5,
RERF-LC-AI, HCT116, SW480, Alexander, HepG2, RT4, MCF7,
Figure 2. H2BK120 methylation is increased in cancer cells. (A) Validation of H2BK120 methylation status in various cell lines. Lysates
from noncancerous cell lines (CCD-18Co and HFL1) and cancer cell lines (SBC5, RERF-LC-AI, HCT116, SW480, Alexander, HepG2, RT4,
MCF7, and HeLa) were immunoblotted with anti-monomethylated K120 H2B, anti–histone H2B (ab1790; Abcam), anti-EZH2 (NCL-L-
EZH2; Leica), and anti-ACTB (No. 4967; Cell Signaling Technology) antibodies. Information of certificated cell lines is described in
Table W4. (B) Quantitative analysis of H2BK120 methylation levels. X-ray films were scanned with GS-800 calibrated densitometer
(Bio-Rad Laboratories). The intensity of each H2BK120 monomethylation signal was normalized by the corresponding H2B signal and
averaged. (C) Tissue microarray images of lung and colon tissues stained by standard immunohistochemistry for the methylation status
of H2BK120. Clinical information for each section is represented in Tables W1 andW2. All tissue samples were purchased from BioChain
(Newark, CA). Original magnification, ×200.
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and HeLa; Table W5), and conducted Western blot analysis using
the specific antibody (Figure 2A). As we expected, the methylation
levels of H2BK120 in cancer cell lines expressing high levels of
EZH2 were higher than in noncancerous cell lines in which EZH2
expression was very low (Figures 2B and W4). We subsequently
conducted immunohistochemical analysis of lung and colon tissues
(one normal lung, three lung squamous cell carcinomas, and two lung
adenocarcinomas as well as one normal colon, one colon adenoma, and
six colorectal adenocarcinomas) using the methylation-specific anti-
body and found higher methylation levels of H2BK120 in cancer cells
than normal cells (Figure 2C , left for lung and right for colon).
H2BK120 Monomethylation Competitively
Inhibits Monoubiquitination
As H2BK120 was shown to be monoubiquitinated and play a
crucial role in the transcriptional regulation, we examined the rela-
tionship between H2BK120 methylation and ubiquitination [9].
Immunocytochemial analysis was conducted after FLAG-tagged
EZH2 expression vectors were transfected into HeLa cells. EZH2-
transfected cells showed significantly lower signals of H2BK120
ubiquitination than control cells (Figure 3A). This result indicated
that EZH2-dependent H2BK120 methylation appears to competi-
tively inhibit the ubiquitination. In addition, we knocked down
the expression of EZH2 in SBC5 cells and conducted the Western
blot analysis using purified histone samples to validate the rela-
tionship between H2BK120 methylation and ubiquitination. Consis-
tently, H2BK120 methylation status of purified histone H2B proteins
was increased after knockdown of EZH2 (Figure 3B). Furthermore,
we examined the status of H2BK120 ubiquitination in normal and
cancer cells and confirmed that ubiquitination levels in cancer cells
were lower than those in noncancerous cells (Figure W5). These results
reveal that the histone methyltransferase EZH2 is likely to inhibit the
Figure 3. H2BK120 methylation competitively inhibited the ubiquitination. (A) Immunocytochemical analysis of HeLa cells. Cells were
stained with an anti–Ubiquityl-Histone H2BK120 antibody (No. 5546; Cell Signaling Technology), an anti-FLAG antibody (M2; Sigma-
Aldrich), and 4′,6′-diamidine-2′-phenylindole dihydrochloride [DAPI (blue)]. Alexa Fluor 488 (green) and Alexa Fluor 594 (red) antibodies
were used as secondary antibodies. HeLa cells were fixed in 4% paraformaldehyde 24 hours after transfection of FLAG-tagged EZH2
expression vectors. (B) Effects of EZH2 knockdown on the ubiquitination of H2BK120 in SBC5 cells. SBC5 cells were lysed 48 hours after
treatment with siNC and siEZH2. Samples were immunoblotted with anti-EZH2 (NCL-L-EZH2; Leica, upper) and anti–Ubiquityl-Histone
H2BK120 (middle) antibodies. Expressions of ACTB (No. 4967; Cell Signaling Technology) and H2B (ab1790; Abcam) were the internal
controls. The ubiquitination level of H2BK120 was calculated by GS-800 (Bio-Rad Laboratories, lower). Results are the means ± SD of
three independent experiments. The P value was calculated using Student’s t test.
1256 EZH2-Dependent H2B-K120 Methylation Kogure et al. Neoplasia Vol. 15, No. 11, 2013
ubiquitination of H2BK120 in a competitive manner through the
methylation of the lysine residue.
Mechanisms in Transcriptional Regulation through
EZH2-Dependent H2BK120 Methylation
As it is known that H2BK120 ubiquitination plays a crucial role in
the transcriptional regulation, we next examined the transcriptional
regulation mechanism of EZH2-dependent H2BK120 methylation
in cancer cells. To identify direct downstream genes of EZH2 through
the methylation of H2BK120, we conducted cDNA microarray and
ChIP-Seq analyses and combined the data. At first, cDNA microarray
analysis using the Affymetrix GeneChip system was performed, and
expression levels of 780 genes were increased after treatment with
siEZH2 in HeLa cells (Figure 4A, more than two times compared with
control). Then, we planned to do ChIP-Seq analysis to examine the
genome-wide H2BK120 monomethylation status. Firstly, we vali-
dated the quality of the antibody whether it is available for immuno-
precipitation or not. FLAG-conjugated wild-type H2B (H2B-WT)
and K120-substituted H2B (H2B-K120A) expression vectors were
Figure 4. Direct downstream genes of EZH2 through the methylation of H2BK120. (A) Schematic diagram of the strategy to identify
direct downstream genes of EZH2. Detailed procedures of ChIP-Seq and microarray analyses were described in Materials and Methods
section. 1) Gene expression profile analysis was conducted using the Affymetrix GeneChip system after knockdown of EZH2 in HeLa
cells. Seven hundred eighty genes were identified to be downregulated by EZH2 knockdown (>2.0). 2) Chip-Seq analysis to examine the
methylation status of histone H2BK120 monomethylation in gene-regulatory regions. Among 780 genes identified by microarray anal-
ysis, the methylation status was decreased in 11 genes. 3) ChIP-Seq analysis to identify binding regions of EZH2 proteins after exog-
enous expression of EZH2. Finally, four genes remained as direct downstream genes of EZH2 through the methylation of H2BK120. (B)
The heatmap of four genes directly regulated by EZH2 through the inhibition of histone H2BK120 methylation. Affymetrix GeneChip data
(microarray analysis) and ChIP-Seq data were combined. G, the expression ratio of each target gene between siEZH2-treated and control
cells (siEZH2/Control). C, the ratio of methylation status in the regulatory region of each gene (siEZH2/Control). Probe Set ID (HG-
U133_Plus_2.na33.annotation) is shown with gene symbol. (C) Expression levels of EZH2, KCNAB1, GNAO1, ATG2B, and MOV10 in
HeLa cells were analyzed by Affymetrix GeneChip system. (D) ChIP analysis using primer pairs of downstream candidate genes as
described under Materials and Methods section. Cross-linked and sheared chromatin was immunoprecipitated with an anti–Ubiquityl-
Histone H2BK120 antibody (No. 5546; Cell Signaling Technology). Protein A Agarose/Salmon Sperm DNA (Millipore) was used as a
negative control. Results are the means ± SD of three independent experiments and shown as a percentage of the input chromatin.
The P value was calculated using Student’s t test.
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transfected into 293T cells, and cell lysates were immunoprecipitated
with anti-H2BK120 methylation antibodies, followed by Western
blot analysis using an anti-FLAG antibody (Figure W6A). Among
three lots of anti-H2BK120 methylation antibodies, H2BK120me1B
showed the best quality as well as slot blot analysis. To evaluate the avail-
ability of this antibody for the immunoprecipitation of endogenous
H2BK1200-methylated proteins, Western blot analysis using the
H2BK120me1B antibody was performed after immunoprecipitation
of SBC5 cell lysates using the same antibody (Figure W6B). Sub-
sequently, we confirmed the specific signal of K120-methylated H2B
proteins, implying that this antibody is also available for the immuno-
precipitation of endogenous K120-methylated histone H2B. On the
basis of this result, ChIP-Seq analysis was conducted after treatment
with siNC (negative control) and two independent siEZH2s, and
among 780 genes selected bymicroarray analysis, the methylation status
of gene-regulatory regions of 11 genes was significantly decreased
(Figure 4A). In addition, we also examined the genome-wide EZH2-
binding status to identify the gene-regulatory regions that EZH2 was
bound by ChIP-Seq analysis. Finally, four genes (KCNAB1, GNAO1,
ATG2B, andMOV10) remained as direct downstream genes of EZH2
through the methylation of H2BK120 after combining the data of
microarray and ChIP-Seq analyses (Figure 4B). Detailed expression pro-
file data of the four genes were shown in Figure 4C . These results reveal
that EZH2-dependent H2BK120 methylation can regulate the tran-
scription of downstream genes, and it is a novel mechanism of human
carcinogenesis mediated by EZH2 overexpression.
Discussion
Histone H2B is a core histone, and so far, acetylation, phosphory-
lation, ubiquitination, and sumoylation have already been reported
as posttranslational modifications of this protein. In the present
study, we identified that lysine 120 of histone H2B is methylated
by EZH2 and that the methylation competitively inhibits the
Figure 5. EZH2-dependent transcriptional regulation mechanism through H2BK120 methylation. (A) Expression of KCNAB1 in cancer
tissues. Expression levels of KCNAB1 are downregulated in various types of cancer. Gene expression data in Oncomine (University of
Michigan, Ann Arbor, MI) were analyzed. The thick bars in the boxes are average expression levels, and the boxes represent 95% of the
samples. The error bars are above or below the boxes, and the range of expression levels is enclosed by two dots. (B) Proposed model
for regulation of H2BK120 posttranslational modification during human carcinogenesis.
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ubiquitination of H2BK120. This is the first report to describe the
function of histone H2B methylation.
In mammals, H2BK120 monoubiquitination was reported to be
preferentially associated with highly transcribed genes [10]. H2BK120
monoubiquitination can cooperate with facilitates chromatin transcrip-
tion (FACT) and the polymerase associated factor (PAF) complex
to regulate transcription elongation by RNA polymerase II [28]
and can also facilitate DNA repair [29] and mRNA 3′ end processing
[11] in human cells. In addition, Vitaliano-Prunier et al. recently re-
ported that H2B ubiquitination in yeast cells plays a role in mRNA
export from the nucleus into the cytoplasm [30]. Importantly, there
are several reports describing the relationship between H2BK120
ubiquitination and cancer. The H2B deubiquitinase ubiquitin specific
peptidase 22 (USP22) is part of a gene signature predictive of a can-
cer stem cell tumor phenotype of aggressive growth, metastasis, and
therapy resistance [31]. RNF20, the E3 ubiquitin ligase for mono-
ubiquitination of H2BK120, is a putative tumor suppressor [32];
its down-regulation in human cells promotes migration, anchorage
independence, and carcinogenesis [32,33]. Furthermore, it was
recently reported that H2B ubiquitination levels were decreased
in advanced and metastatic breast cancer, parathyroid tumors, and
seminoma [34–36]. These data imply that H2BK120 ubiquitination
appears to possess tumor-suppressive functions, and its dysfunction
causes malignant alteration of human cells.
In this study, we demonstrated that the histone methyltransferase
EZH2 methylated H2BK120 and competitively inhibited the ubiqui-
tination and that in cancer cells, the methylation level was increased,
and the ubiquitination was decreased at lysine 120 of histone H2B.
From these results, H2BK120 ubiquitination shows tumor-suppressive
functions, and the oncogenic polycomb histone methyltransferase
EZH2 competitively inhibits the ubiquitination through the methyla-
tion of H2BK120, which may result in the reduction of tumor-
suppressive effects. In addition, we identified direct downstream genes
of EZH2 through the methylation of H2BK120 on the basis of ChIP-
Seq and microarray analyses (Figure 4A). Importantly, ChIP analysis
indicated that H2BK120 ubiquitination levels of downstream candi-
date genes were significantly high in nontumor cells, implying that
these genes may be transcriptionally activated in nontumor cells
through the H2BK120 ubiquitination (Figure 4D). Among direct
downstream candidates we identified, expression levels of KCNAB1
andGNAO1 are significantly decreased in various types of tumor tissues
(Figures 5A and W7). KCNAB1 is a voltage-gated potassium channel β
subunit and modulates the activity of the pore-forming α subunit
[37,38]. It has already been reported that some components of potas-
sium channel serve as tumor suppressors. KCTD11 (potassium channel
tetramerization domain containing 11) is a novel tumor suppressor gene
that inhibits cell growth and is mapping on human chromosome
17p13.2 [39]. According to the research using a panel of 177 human
tumor samples and their normal matching samples representing 18 dif-
ferent types of cancer, down-regulation of KCTD11 protein level is a
diffusely common event in tumorigenesis [40]. In addition, the putative
tumor suppressorKCNRG (potassium channel–regulating gene) encodes
a protein with a high homology to the tetramerization domain of
voltage-gated K+ (Kv) channels [41]. This protein appears to inter-
fere with the normal assembly of the K+ channel proteins by binding
to their tetramerization domain, thereby causing the suppression of
Kv currents [42]. Because Kv channels are involved in the prolifer-
ation of tumor cells [43] and normal lymphocytes [44], while being
upregulated in neoplastic hematopoietic cells [45], KCNRG seems
to exert a tumor suppressor effect [41]. On the contrary, GNAO1,
a member of the signal-transducing guanine nucleotide-binding (G)
protein family, has been implicated in ion channel regulation [46],
and mutation of GNAO1 was reported to cause the malignant alter-
ation of cells [47,48]. GPRC5a, a family gene of GNAO1, is reported
as a tumor suppressor gene, and knockout of GPCR5 leads to NF-κB
activation in airway epithelium and promotes lung tumorigenesis [49].
Furthermore, according to expression profile analysis, expression levels
of ATG2B, one of the autophagy-related genes, in several types of
tumor tissues were much lower than those in corresponding normal
tissues (Figure W8). Frameshift mutations of ATG2B were found in
gastric and colorectal cancers [50]. The truncation mutants of ATG2B
may inactivate its autophagy function and/or autophagic cell death,
which resembles a typical loss-of-function mutation. These data imply
that KCNAB1, GNAO1, and ATG2B are likely to be deregulated in
cancer and work as tumor suppressors. Taken together, the oncogenic
histone methyltransferase EZH2 is likely to contribute to human
carcinogenesis based on the transcriptional regulation of downstream
genes through not only H3K27 methylation but also H2BK120 meth-
ylation. In line with this, we also conducted the ChIP-Seq analysis
and found that GNAO1, ATG2B, and MOV10 were regulated by
H2BK120 methylation, but the KCNAB1 gene appears to be regulated
by both H2BK120 methylation and H3K27 methylation (Table W6).
This implies that some gene is likely to be synergistically regulated by
two different histone marks.
All the while, histone H3-K27 has been only the known target of
EZH2-dependent methylation, and the importance of EZH2 in
human carcinogenesis was described only focusing on H3K27 meth-
ylation. In this study, we identified H2BK120 to be a novel target of
EZH2-dependent methylation and downstream candidates through
the novel methylation site (Figure 5B). Because EZH2 is over-
expressed in various types of cancer and it plays a critical role in the
growth regulation of cancer cells, EZH2 is recognized as an important
target of anticancer treatment. In fact, chemical compounds, which
inhibit methyltransferase activity of EZH2, have recently been devel-
oped as anticancer drugs. According to our findings, we need to
take care of H2BK120 methylation besides H3K27 methylation to
develop efficient anticancer treatment targeting EZH2, and the iden-
tification of this novel methylation site must contribute to unveil the
multifunctions of EZH2 in human carcinogenesis. Furthermore,
additional functional analysis of H2BK120 methylation may eluci-
date the significance of biologic function of this methylation, includ-
ing disease like cancer, and the importance for diagnosis, prognosis,
and treatment for cancer.
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Table W3. siRNA Sequences.
siRNA Name Sequence
siNC (cocktail)
Target No. 1 Sense: 5′ AUCCGCGCGAUAGUACGUA3′
Antisense: 5′ UACGUACUAUCGCGCGGAU 3′
Target No. 2 Sense: 5′ UUACGCGUAGCGUAAUACG 3′
Antisense: 5′ CGUAUUACGCUACGCGUAA 3′
Target No. 3 Sense: 5′ UAUUCGCGCGUAUAGCGGU 3′
Antisense: 5′ ACCGCUAUACGCGCGAAUA 3′
siEZH2 No. 1 Sense: 5′ CUAACCAUGUUUACAACUA 3′
Antisense: 5′ UAGUUGUAAACAUGGUUAG 3′
siEZH2 No. 2 Sense: 5′ GACAGAAGAGGGAAAGUGU 3′
Antisense: 5′ ACACUUUCCCUCUUCUGUC 3′
Table W1. Characteristics of Lung Tissues.
Case No. Age Gender Pathology Grade Stage (TNM) Nature
Case 1 34 Male Normal Normal
Case 2 58 Male Squamous cell carcinoma II T2N0M0 Malignant
Case 3 42 Male Squamous cell carcinoma II T2N0M0 Malignant
Case 4 57 Male Squamous cell carcinoma III T2N0M0 Malignant
Case 5 62 Male Adenocarcinoma II T2N0M0 Malignant
Case 6 73 Male Adenosquamous carcinoma III T2N1M0 Malignant
Table W2. Characteristics of Colon Tissues.
Case No. Age Gender Histology Grade Stage (TNM) Anatomic Site
Case 1 49 Female Normal Colon
Case 2 65 Male Adenoma Colon
Case 3 51 Male Adenocarcinoma II T3N1M0 Colon
Case 4 39 Female Adenocarcinoma I_II T3N1M0 Colon
Case 5 49 Female Adenocarcinoma I_II T3N0M0 Colon
Case 6 62 Female Adenocarcinoma I_II T2N1M0 Colon
Case 7 60 Male Adenocarcinoma II T2N1M0 Colon
Case 8 34 Male Adenocarcinoma I T3N0M0 Colon
Table W4. Primer Sequences for ChIP Analysis.
Name Sequence Length Tm (°C) MW
KCNAB1 Set 1 (KCNAB1-1): Amplification Size = 123
KCNAB1-ChIP-f1 TTC CGT GTT CGA AGA TAC CAC 21 59.5 6381.2
KCNAB1-ChIP-r1 AAC CTT ATC CTG CCA CAA AGC 21 59.5 6319.2
KCNAB1 Set 2 (KCNAB1-2): Amplification Size = 119
KCNAB1-ChIP-f2 ATT TGT CAG AAG TGC TGG GAG G 22 62.1 6870.5
KCNAB1-ChIP-r2 TCT TTG AAT GTC AGT GAA CCA C 22 58.4 6709.4
GNAO1 Set 1 (GNAO1-1): Amplification Size = 139
GNAO1-ChIP-f1 AGC CTC GGG TGT CAC ATA TTA G 22 62.1 6750.4
GNAO1-ChIP-r1 CTC AGG AAA CGC GAT GTG GTA G 22 64.2 6824.5
GNAO1 Set 2 (GNAO1-2): Amplification Size = 118
GNAO1-ChIP-f2 ATT CCG ACC CAC TAC CAC ATC 21 61.2 6255.1
GNAO1-ChIP-r2 GGG CCG GCT CTC CAT CTT GTC 21 67.3 6365.2
ATG2B Set 1 (ATG2B-1): Amplification Size = 122
ATG2B-ChIP-f1 TCG GAG CCG GAA CTG CTC CAG 21 67.3 6432.2
ATG2B-ChIP-r1 CTC CTG GCG CGT TCA CGA GAC 21 67.3 6383.2
ATG2B Set 2 (ATG2B-2): Amplification Size = 98
ATG2B-ChIP-f2 CCA GGA TTA AGC GAG CGT ATG 21 61.2 6495.3
ATG2B-ChIP-r2 CCC CGC CTC ATT CAG GTA TTG 21 63.2 6333.2
MOV10 Set 1 (MOV10-1): Amplification Size = 149
MOV10-ChIP-f1 TTC CCA CTG ACA TTG CAT TTC 21 57.5 6307.2
MOV10-ChIP-r1 AGG CCA CAC ACT CAA TCT ACG 21 61.2 6344.2
MOV10 Set 2 (MOV10-2): Amplification Size = 104
MOV10-ChIP-f2 TTA CTG TGT ATC CTG GCA GAG C 22 62.1 6741.4
MOV10-ChIP-r2 CAT AAG GGT CAA AGA AGT TTG G 22 58.4 6847.6
Tm indicates melting temperature; MW, molecular weight.
Figure W1. EZH2 methylates histone H2B. In vitro methyltrans-
ferase of EZH2 was performed using various types of recombi-
nant proteins as substrates. Methylated proteins were visualized
with fluorography.
Figure W2. Quality check of peptides used as immunogens. (A) Amino acid sequence of the peptide. Ninth lysine residue is monomethy-
lated. (B) Mass spectrum of the peptide. Bruker Daltonics flexAnalysis software (Billerica, MA) was used for the analysis. (C) Chromatogram
of the peptide analyzed by the MultiStation LC-8020 system. (D) Isoelectric point figure of the peptide.
Figure W3. Slot blot analysis for the quality check of antibodies. In vitro methyltransferase assays were performed using recombinant
EZH2 enzyme complex (No. 51004; BPS Bioscience) as an enzyme source. Samples were fractionated with SDS-PAGE and transferred
to the nitrocellulose membranes. Slot blot analysis was conducted using anti-H2BK120 antibodies. An anti–histone H2B antibody was
used as an internal control.





DNA Profile or Characteristics
CCD-18Co human colonic fibroblast ATCC STR Amelogenin: X CSF1PO: 8 D13S317: 12 D16S539: 12,13 D5S818:
12 D7S820: 8 THO1: 6,7 TPOX: 8,11 vWA: 15,17
HFL1 human fetal lung fibroblast ATCC STR Amelogenin: X,Y CSF1PO: 10,12 D13S317: 11,12 D16S539: 9,11
D5S818: 12 D7S820: 9,10 THO1: 7,9 TPOX: 6,9 vWA: 17
SBC5 human small lung cancer JCRB STR Amelogenin: X,Y TPOX: 9,12 CSF1PO: 10 D5S818: 10,11
D13S317: 8,10 D7S820: 8,11 D16S539: 12 vWA: 14,18 TH01: 6
RERF-LC-AI human lung squamous cell carcinoma JCRB STR Amelogenin: X,Y TPOX: 10,11 CSF1PO: 12 D5S818: 10.3
D13S317: 10 D7S820: 10,11 D16S539: 11 VWA: 17 TH01: 7,9
HCT116 human colorectal carcinoma ATCC STR Amelogenin: X,Y CSF1PO: 7,10 D13S317: 10,12 D16S539: 11,13
D5S818: 10,11 D7S820: 11,12 THO1: 8,9 TPOX: 8,9 vWA: 17,22
SW480 human colorectal carcinoma ATCC STR Amelogenin: X CSF1PO: 13,14 D13S317: 12 D16S539: 13
D5S818: 13 D7S820: 8 THO1: 8 TPOX: 11 vWA: 16
Alexander human malignant liver cancer JCRB STR D5S818: 12 D13S317: 11,12 D7S820: 9,11 D16S539: 13
vWA: 15,16 TH01: 7,8 Amelogenin: X TPOX: 8 CSF1PO: 10
RT4 human urinary bladder cancer ATCC STR Amelogenin: X,Y CSF1PO: 10,12 D13S317: 8 D16S539: 9 D5S818: 11,12
D7S820: 9,12 THO1: 9,9.3 TPOX: 8,11 vWA: 14,17
MCF7 human breast adenocarcinoma ATCC STR Amelogenin: X CSF1PO: 10 D13S317: 11 D16S539: 11,12 D5S818: 11,12
D7S820: 8,9 THO1: 6 TPOX: 9,12 vWA: 14,15
HeLa human cervix carcinoma ATCC STR Amelogenin: X,Y CSF1PO: 11,12 D13S317: 11,14 D16S539: 9,11
D5S818: 11,12 D7S820: 10,11 THO1: 8 TPOX: 8 vWA: 15
ATCC indicates American Type Culture Collection; JCRB, Japanese Collection of Research Bioresources.
Figure W4. Quantitative analysis of EZH2 expression in various types
of cell lines. X-ray films were scanned with GS-800 calibrated densi-
tometer (Bio-Rad Laboratories). The intensity of each EZH2 signal
was normalized by the corresponding ACTB signal and averaged.
Figure W5. H2BK120 ubiquitination was decreased in cancer cells. (A) Validation of H2BK120 ubiquitination status in various cell lines.
Lysates from a noncancerous cell line (CCD-18Co) and cancer cell lines (RERF-LC-AI, A549, ACC-LC-319, Alexander, SNU475, MCF7,
HepG2, and UMUC3) were immunoblotted with anti–Ubiquityl-Histone H2BK120 antibody (No. 5546; Cell Signaling Technology) and
anti–histone H2B (ab1790; Abcam) antibodies. (B) Quantitative analysis of H2BK120 ubiquitination levels. X-ray films were scanned with
GS-800 calibrated densitometer (Bio-Rad Laboratories). The intensity of each H2BK120 ubiquitination signal was normalized by the
corresponding H2B signal and averaged.
Figure W6. Validation of anti-H2BK120 methylation antibodies. (A)
Wild-type FLAG-H2B (H2B-WT) and lysine 120–substituted FLAG-
H2B expression vectors (K120A) were transfected into 293T cells.
Cell lysates were immunoprecipitated with anti-H2BK120 methyl-
ation antibodies, and immunoblot analysis was performed using an
anti-FLAG antibody (M2; Sigma-Aldrich). (B) SBC5 cells were lysed
with CelLytic M, and cell lysates were immunoprecipitated with
an anti-H2BK120 methylation antibody. Whole-cell extracts were
blotted with an antihistone H2B antibody (Abcam; ab1790).
Figure W7. Expression of GNAO1 in cancer tissues. Expression levels of GNAO1 are downregulated in various types of cancer. Gene
expression data in Oncomine were analyzed. The thick bars in the boxes are average expression levels, and the boxes represent 95% of
the samples. The error bars are above or below the boxes, and the range of expression levels is enclosed by two dots.
Figure W8. Expression of ATG2B in cancer tissues. Expression levels of ATG2B are downregulated in various types of cancer. Gene
expression data in Oncomine were analyzed. The thick bars in the boxes are average expression levels, and the boxes represent 95% of
the samples. The error bars are above or below the boxes, and the range of expression levels is enclosed by two dots.
Table W6. Comparison of H2BK120 Monomethylation and H3K27 Trimethylation Status in the
Gene-Regulatory Regions of Downstream Candidates.





*Value is the ratio of tag number (siEZH2/siNC).
†NA; No significant methylation was detected in both siEZH2 and siNC samples.
